Institute of Human Virology Nigeria/ University of Maryland
University of Maryland
National Institutes of Health
With correct strategies such as screening and vaccination, cervical cancer caused by Human Papillomavirus (HPV) can be prevented entirely. However, many African women are unable to access screening programs or vaccines, causing this preventable disease to be especially deadly across the contient. By understanding the genomic risk and the role of the vaginal microbiome in persistence of HPV infection and cervical cancer progression, scientists and doctors can develop screening and prevention strategies to identify at-risk individuals and reduce their risk of cervical cancer.
Through genomic sequencing, ACCME has been able to demonstrate a wide range of associations between genomic variants and the types of bacteria present in the vaginal microbiome, and risk of persistent hrHPV infection and cervical cancer. To understand the full picture of genomic factors, vaginal microbiome, and hrHPV infection and cervical cancer progression, the group is continuing to generate insights into the genomic factors and vaginal microbiome of women with and those without HPV infections. These inslights may enable novel strategies for treatment and prevention of cervical cancer.
Institute of Human Virology Nigeria, University of Ibadan, African Univeristy of Science and Technology, National Hospital Abuja, Covenant Univeristy
Center for Infectious Disease Research in Zambia, University of Zambia
USA: Greenebaum Comprehensive Cancer Center, Institute of Human Virology and Institute of Genome Sciences, University of Maryland School of Medicine, National Institutes of Health, University of New Mexico
UK: Queen Mary University of London